Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 1.00 |
| ▸ | LCK | P06239 | 11/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 1.00 |
| ▸ | TEK | Q02763 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.85 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 3/20 | 0.75 |
| ▸ | EGFR | P00533 | 5/20 | 0.68 |
| ▸ | ITK | Q08881 | 3/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.68 |
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | FYN | P06241 | 2/20 | 0.68 |
| ▸ | HCK | P08631 | 2/20 | 0.68 |
| ▸ | FER | P16591 | 2/20 | 0.68 |
| ▸ | CSK | P41240 | 2/20 | 0.68 |
| ▸ | BLK | P51451 | 2/20 | 0.68 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430567 | 1.00 | BTK (1.00) | BTKLCKSRCTEKKDR | |
| SCHEMBL29763088 | 1.00 | BTK (1.00) | BTKLCKSRCTEKKDR | |
| SCHEMBL6430568 | 1.00 | BTK (1.00) | BTKLCKSRCTEKKDR | |
| SCHEMBL5804616 | 0.94 | BTK (0.93) | BTKLCKSRCTEKKDR | |
| SCHEMBL6434063 | 0.93 | BTK (0.86) | BTKLCKSRCTEKKDR | |
| SCHEMBL21341768 | 0.92 | BTK (1.00) | BTKLCKSRCTEKKDR | |
| SCHEMBL6432477 | 0.91 | LCK (0.83) | BTKLCKSRCTEKKDR | |
| SCHEMBL6432474 | 0.91 | LCK (0.83) | BTKLCKSRCTEKKDR | |
| SCHEMBL6430895 | 0.91 | LCK (0.83) | BTKLCKSRCTEKKDR | |
| SCHEMBL5789383 | 0.91 | LCK (0.83) | BTKLCKSRCTEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2878601-A1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | Riken (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, BCOR, RUNX1 | BTK 3219/4885LCK 3635/4885SRC 395/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | BTK 1020/4885LCK 1011/4885SRC 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.